Arkansas Teacher Retirement System, et al. v. Insulet Corp., et al.
|Court:||United States District Court for the District of Massachusetts|
|Judge:||Hon. Mark L. Wolf|
|Class Period:||05/07/2013 - 04/30/2015|
|Case Contacts:||James A. Harrod, Rebecca E. Boon|
This is a securities fraud class action filed on behalf of a class of persons and entities who purchased or acquired Insulet Corporation’s (“Insulet” or the “Company”) publicly traded common stock from May 7, 2013 to April 30, 2015, inclusive (the “Settlement Class Period”). Lead Plaintiffs allege that Insulet and certain of its senior officers (collectively, “Defendants”) defrauded investors by misrepresenting the success of a new version of the Company’s core product—the OmniPod Eros, a wearable insulin infusion pump that represented 81% of Insulet’s revenue.
Lead Plaintiffs Have Reached a Proposed Settlement for $19.5 Million
The Court-appointed Lead Plaintiffs, Arkansas Teacher Retirement System, the City of Bristol Pension Fund, and the City of Omaha Police & Fire Retirement System, have reached a proposed settlement of this action for $19,500,000 in cash that, if approved by the Court, will resolve all claims in the action.
If you are a member of the Settlement Class, your rights will be affected and you may be eligible for a payment from the settlement. The Settlement Class consists of:
all persons who purchased Insulet common stock during the period commencing on May 7, 2013 through April 30, 2015, inclusive, except for certain persons and entities who are excluded from the Settlement Class by definition (see, Question 3 on page 6 of the Notice).
Please read the Notice to fully understand your rights and options. Copies of the Notice and Claim Form can be found on the Case Documents page. You may also visit the Settlement website, www.InsuletSecuritiesLitigation.com, for more information about the Settlement.
If you are a member of the Settlement Class, in order to be potentially eligible to receive a payment under the proposed Settlement, you must submit a Claim Form postmarked no later than September 4, 2018. Payments to eligible claimants will be made only if the Court approves the settlement and a plan of allocation, and only after any appeals are resolved, and after the completion of all claims processing. Please be patient, as this process will take some time to complete.
IMPORTANT DATES AND DEADLINES
September 4, 2018
Claim Filing Deadline. Claim Forms must be postmarked no later than September 4, 2018 to be eligible for a payment from the Settlement.
August 2, 2018
Settlement Hearing. The Settlement Hearing will be held on August 2, 2018 at 2:30 p.m., in the Courtroom of the Honorable Mark L. Wolf, at the United States District Court for the District of Massachusetts, John Joseph Moakley U.S. Courthouse, 1 Courthouse Way, Boston, MA 02210, to determine, among other things, whether the proposed Settlement is fair, reasonable and adequate and should be approved; whether the proposed Plan of Allocation is fair and reasonable and should be approved; and whether Lead Counsel’s motion for an award of attorneys’ fees and reimbursement of expenses should be approved.
In this Action, Lead Plaintiffs allege that Defendants made materially false and misleading statements to investors touting the quality of the OmniPod Eros, the successful launch of the product, customers’ broad acceptance of the product, and the high rate of new patient starts during the Settlement Class Period. Lead Plaintiffs allege that, in reality, the OmniPod Eros was plagued by defects that not only affected customer acceptance and demand, but also the Company’s revenue and that—rather than disclosing the truth, nature, and extent of these defects—Defendants continued to authorize shipment of the product over the objections of the Company’s quality assurance department and continued to misrepresent the number of new patients beginning to use the product.
Lead Plaintiffs further allege that truth was revealed through a series of corrective disclosures starting in early 2015. On January 7, 2015, Insulet disclosed that its fourth quarter 2014 revenue would be $5 to $8 million less than its prior guidance due to reduced demand for the OmniPod Eros. The same day, the Company announced that its new CEO was replacing six senior executives. A week later, the CEO warned that analysts’ estimates of the Company’s performance for 2015 were too high, and he simultaneously disclosed that the launch of the Eros product had been much less successful than the Company had claimed. Finally, in February 2015, Insulet announced its fourth quarter 2014 earnings, which revealed that sales of the product in the United States were worse than originally thought. The price of Insulet shares fell significantly in response to each of these disclosures.
Plaintiffs filed the initial Complaint in this action in June 2015 and an Amended Complaint in June 2016. In March 2016, the Court appointed the Arkansas Teacher Retirement System, the City of Bristol Pension fund, and the City of Omaha Police and Retirement Fund as Lead Plaintiffs and appointed BLB&G as co-Lead Counsel. Defendants moved to dismiss the securities claims in August 2016; after a hearing in March 2017, the Court denied Defendants’ motion to dismiss.
Discovery in the Action commenced in April 2017. Defendants and over two dozen third parties produced a total of more than 130,000 pages of documents (exclusive of voluminous files of computerized data) in response to Lead Plaintiffs’ requests for production of documents and third-party subpoenas.
On July 20, 2017 counsel for Lead Plaintiffs and for Defendants participated in a lengthy, in-person mediation session before David Geronemus, Esq. of JAMS, a highly experienced mediator of complex actions, but no agreement was reached. Only after months of additional negotiations, on November 27, 2017, the Parties (with the assistance of the Mr. Geronemus) were able to reach an agreement in principle to settle the Action
On February 8, 2018, the Parties entered into a Stipulation and Agreement of Settlement (the “Stipulation”), which sets forth the final and complete terms and conditions of the Settlement. If approved by the Court, the Settlement will settle and release all claims asserted in the Action in return for a $19.5 million cash payment.
Other Cases of Interest
- Signet Jewelers Limited
Southern District of New York John Rizio-Hamilton, Rebecca E. Boon, Michael Mathai, Brenna Nelinson
- Express Scripts Holding Company
Southern District of New York Salvatore J. Graziano, Rebecca E. Boon, Adam Hollander
- Vale SA
Southern District of New York John C. Browne, Timothy A. DeLange, Richard D. Gluck, Rebecca E. Boon, Robert Trisotto
- Volkswagen AG
Northern District of California Gerald H. Silk, Avi Josefson, James A. Harrod, Jeroen van Kwawegen, Ross Shikowitz, Adam Hollander
- Symantec Corporation
Northern District of California David R. Stickney, Jeroen van Kwawegen, Lucas E. Gilmore, Rebecca E. Boon
- Micro Focus International, plc
Southern District of New York James A. Harrod, Jai K. Chandrasekhar, Julia Tebor
- Henry Schein, Inc.
Eastern District of New York James A. Harrod, Michael Mathai
- Wells Fargo & Company
Northern District of California Salvatore J. Graziano, Adam H. Wierzbowski, Rebecca E. Boon, Michael Mathai
- Green Mountain Coffee Roasters, Inc.
District of Vermont John C. Browne, Rebecca E. Boon, Julia Tebor